Handelsbanken Fonder
CRNX icon

Handelsbanken Fonder’s Crinetics Pharmaceuticals CRNX Stock Holding History

Handelsbanken Fonder’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
36,000
+6,500
+22% +$242K ﹤0.01% 996
2026
Q1 		$1.07M Hold
29,500
– – ﹤0.01% 1002
2025
Q4 		$1.37M Sell
29,500
-2,600
-8% -$116K ﹤0.01% 902
2025
Q3 		$1.34M Buy
32,100
+7,600
+31% +$243K ﹤0.01% 889
2025
Q2 		$705K Buy
24,500
+2,700
+12% +$83.4K ﹤0.01% 1104
2025
Q1 		$731K Hold
21,800
– – ﹤0.01% 1074
2024
Q4 		$1.11M Buy
21,800
+2,800
+15% +$157K ﹤0.01% 922
2024
Q3 		$971K Buy
19,000
+2,600
+16% +$134K ﹤0.01% 956
2024
Q2 		$735K Buy
16,400
+3,100
+23% +$143K ﹤0.01% 982
2024
Q1 		$623K Buy
13,300
+800
+6% +$31.3K ﹤0.01% 1064
2023
Q4 		$445K Buy
+12,500
New +$383K ﹤0.01% 1205

Other funds holding CRNX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Handelsbanken Fonder's CRNX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Crinetics Pharmaceuticals (CRNX) stake by 22% in Q2 2026, buying an estimated $242K and bringing the position to 36,000 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Handelsbanken Fonder first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.37M in Q4 2025. 54 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Handelsbanken Fonder held 36,000 shares of Crinetics Pharmaceuticals worth $1.35M as of Q2 2026.
  • Handelsbanken Fonder bought 6,500 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $242K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #996 holding.
  • Handelsbanken Fonder first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Handelsbanken Fonder's Crinetics Pharmaceuticals position peaked at $1.37M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.